The acquisition is a strategic bolt-on that diversifies argenx's immunology platform beyond FcRn into T-cell/NK-cell biology with early clinical validation. Watch for HSR clearance and tender results in Q3; Phase 2 celiac data in H2 2026 is the next major catalyst for FB102. The all-cash structure removes financing risk, and the premium reflects argenx's conviction in FB102's pipeline-in-a-product potential.
Drugs in focus
ARGX drug pipeline →empasiprubart
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- Several years away, if successful. Phase 3 MMN trial won't complete final data collection until December 2029. A potential BLA submission would follow positive Phase 3 data, likely no earlier than 2027-2028.
- Next catalyst
- None dated
What to watchWatch for Phase 3 topline MMN data (estimated primary completion Sep 2026). Positive data could add a new pipeline pillar, but empasiprubart is not the primary value driver at argenx, Vyvgart's commercial trajectory and the myositis readout for efgartigimod are larger stock-moving events. A Phase 2 dermatomyositis readout is also expected by November 2026.
- ▲ efgartigimod 4/10 Approved (Phase 3 for pipeline expansion) Named in filing
- ● FB102 4/10 Phase 1b (proof-of-concept completed); Phase 2 (celiac disease) ongoing Named in filing
- ● TSP-101 2/10 Phase 1
- ● ARGX-109 1/10 Preclinical / Discovery
- ● ARGX-118 1/10 Unknown — not found in any clinical trial registry or pipeline disclosure.
- 3 more · All ARGX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 27 $888.82entry
- T+1 · 4mo ago −1.87%α −2.11% · $872.23
- T+5 · 4mo ago −3.94%α −5.01% · $853.82
- T+20 · 3mo ago +13.76%α +10.46% · $1,011.11
- T+60 · 28d ago −7.11%α −10.82% · $825.61
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
argenx is acquiring Forte Biosciences for $77/share in cash, total equity value ~$2.2B, an 86% premium to Forte's VWAP since positive Phase 1b vitiligo data. The deal adds FB102, a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease, fitting argenx's strategy to expand its immunology pipeline beyond FcRn blockade. The acquisition is fully funded from cash on hand and expected to close in Q3 2026, with no financing condition, a disciplined bolt-on that broadens argenx's T-cell/NK-cell targeting capability without diluting shareholders.
Key Financial Metrics
Key Facts
- argenx acquires Forte Biosciences for $77/share cash, ~$2.2B total equity value
- 86% premium to Forte's VWAP since July 9, 2026 positive Phase 1b vitiligo data
- FB102 is a first-in-class anti-CD122 antibody with Phase 1b proof-of-concept in vitiligo and celiac disease
- Phase 2 celiac data expected H2 2026; potential in alopecia areata and other autoimmune diseases
- Transaction fully funded from cash on hand, no financing condition
- Expected to close in Q3 2026, subject to HSR and tender of majority of shares
- Goldman Sachs and Freshfields advising argenx; Guggenheim and Wilson Sonsini advising Forte
Financial Impact
$2.2 billion total equity value at $77/share cash, 86% premium to unaffected VWAP
Risk Factors
- HSR antitrust review could delay or impose conditions
- Phase 2 celiac data may not replicate Phase 1b results
- Integration risk and potential distraction from core efgartigimod franchise
- Competition from other T-cell targeting therapies in development
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3333257 |
Track record
23 reports on ARGX
6 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +30.22% at T+60 after the Jun 3, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 9, 20267d ago 6-K Bullish 6/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 9, 20267d ago 6-K Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $962.27 Now $950.95 −1.18% settles Dec 8
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $894.77 Now $950.95 +6.28% settles Dec 4
- Oct 29, 202618d ago Institutional Cluster Neutral 3/10 Entry $897.85 Now $950.95 +5.91% settles Nov 27
- Oct 22, 202625d ago 6-K Bullish 6/10 Entry $875.76 Now $950.95 +8.59% settles Nov 19
- Oct 19, 202628d ago 6-K Bullish 7/10 Entry $825.61 to $950.95 Now $950.95 +15.18% ▲ +15.18% +18.64% vs SPY
- Oct 8, 20265w ago 6-K Mixed 6/10 Entry $818.63 to $931.38 Now $950.95 +16.16% ▲ +13.77% +19.06% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $970.66 to $871.52 Now $950.95 −2.03% ▼ −10.21% −10.87% vs SPY
- Sep 10, 20269w ago Institutional Cluster Mixed 5/10 Entry $984.04 to $818.63 Now $950.95 −3.36% ▼ −16.81% −18.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers